The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 498.00
Bid: 496.00
Ask: 500.00
Change: -15.00 (-2.97%)
Spread: 4.00 (0.806%)
Open: 506.00
High: 506.00
Low: 490.00
Prev. Close: 505.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement Regarding Restore plc

10 Aug 2021 07:00

RNS Number : 1254I
Marlowe PLC
10 August 2021
 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE").

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

FOR IMMEDIATE RELEASE.

 

10 August 2021

Marlowe plc

 

Statement Regarding Restore plc ("Restore")

 

Further to the announcement of 22 July 2021 regarding a possible offer to acquire all of the issued and to be issued share capital of Restore, the Board of Marlowe plc ("Marlowe" or, the "Company" or, together with its group, the "Group") does not believe that a transaction is able to be reached on financial terms that would be in the best interests of Marlowe shareholders. As such, Marlowe confirms that it does not intend to make an offer for Restore under Rule 2.7 of the Code. This is a statement to which Rule 2.8 of the Code applies.

 

The Marlowe Board (the "Board") continues to believe that a combination of Marlowe and Restore would have been strategically compelling, creating a business of scale delivering a broad spectrum of complementary business-critical services and software to UK organisations and providing a platform for significant future growth. The Board believes that the Marlowe management team has demonstrated a strong track record in creating value for shareholders and understands the growth opportunities that the combined group would have been able to capitalise upon.

 

In line with Marlowe's disciplined approach to M&A, and taking into account the Board's view of the relative growth prospects of both businesses and inherent value of each, the Board does not believe that a combination with Restore at an offer price that would be required to secure a recommendation from the Restore Board would deliver attractive value creation for Marlowe shareholders.

 

For the purposes of Rule 2.8 of the Code, Marlowe, and any person(s) acting in concert with it, reserve the right to make or participate in an offer or possible offer for Restore (and/or take any other action which would otherwise be restricted under Rule 2.8 of the Code) within six months of the date of this announcement:

a. with the agreement of the board of directors of Restore;

b. following the announcement of a firm intention to make an offer for Restore by or on behalf of a third party;

c. following the announcement by Restore of a proposal for a "whitewash" (as referred to in Note 1 of the Notes on Dispensations from Rule 9 of the Code) or for a reverse takeover (as defined in the Code); or

d. where the Panel on Takeovers and Mergers (the "Panel") has determined that there has been a material change of circumstances.

 

Further strategic and operational progress in delivering the Marlowe medium-term growth strategy:

 

The Board remains focused on delivering on the strategy outlined at the Capital Markets Day on 17 February 2021 with attractive future growth opportunities across the business-critical service and software markets and is highly confident of the Group's future standalone prospects:

 

- Deepen & Broaden: Current run rate revenues and adjusted EBITDA of approximately £290m and £50m respectively

- Strengthen: Group has been trading ahead of the Board's expectations in the first half of its financial year, including strong organic growth

o Divisional adjusted EBITDA margin currently approximately 18% on an underlying basis

- Digital: SaaS Annual Recurring Revenues now approximately £25m

- 2024 Targets: Board has confidence in achieving its target of £100m run rate adjusted EBITDA ahead of its original target of the end of FY2024

 

Marlowe's current run rate revenues are approximately £290m and the Group has been trading ahead of the Board's expectations in the first half of its financial year. Marlowe continues to build its organic base of recurring revenues and has achieved good levels of organic growth since the start of the current financial year. In addition, the Group continues to make strong progress in driving productivity, efficiency and margin enhancement, with divisional adjusted EBITDA margin continuing to increase towards the Group's three-year target of 20% and currently standing at approximately 18% on an underlying basis.

 

In the last 12 months, Marlowe has deployed £182m of capital on 22 acquisitions with a positive contribution of approximately £22m before synergies to the Group's run rate adjusted EBITDA, whilst deepening and broadening its capabilities across the business-critical service and software sectors that it occupies. Following recent acquisitions, Group run rate adjusted EBITDA is currently approaching £50m, up from £37m as announced in our Capital Markets Day and Trading Update of 17 February 2021. SaaS annual recurring revenues, in line with the Group's digital strategy and following the recently announced £18m acquisition of CoreStream and £32m acquisition of Barbour EHS from Informa plc, are currently approximately £25m.

 

The Group's pipeline of acquisitions to add further scale and breadth to the existing platform continues to develop and it expects to report on further M&A progress in the coming weeks. The Group's balance sheet remains in a strong position to execute upon its M&A strategy.

 

The combination of organic growth expectations, further margin expansion and M&A strategy underpin the Board's confidence in achieving its target of £100m run rate adjusted EBITDA ahead of its original target of the end of FY2024.

 

 

For further information contact:

Marlowe plc

+44 (0) 203 813 8498 /

IR@marloweplc.com

Alex Dacre, Chief Executive

Mark Adams, Group Finance Director

Goldman Sachs International (Financial Adviser to Marlowe)

+44 20 7774 1000

Owain Evans

Khamran Ali

Pernille Thuesen

Bertie Whitehead (Corporate Broking)

Tom Hartley (Corporate Broking)

FTI Consulting (PR Adviser to Marlowe)

+44 20 3727 1340

Nick Hasell

Alex Le May

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 20 7397 8900

Nicholas Wells

Ben Jeynes

George Lawson

Berenberg (Joint Broker)

+44 20 3207 7800

Ben Wright

Mark Whitmore

 

 

Important notices

 

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction, whether pursuant to this announcement or otherwise.

 

The release, distribution or publication of this announcement in jurisdictions outside the United Kingdom may be restricted by laws of the relevant jurisdictions and therefore persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

 

Disclaimer

 

Goldman Sachs International, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the PRA and the Financial Conduct Authority ("FCA") in the United Kingdom, is acting exclusively for Marlowe plc and for no one else and will not be responsible to anyone other than Marlowe plc for providing the protections afforded to its clients or for providing advice in relation to the contents of this announcement or any other matters referred to in this announcement.

 

Cenkos Securities plc ("Cenkos"), which is authorised and regulated by the FCA, is acting exclusively for Marlowe and no one else and will not be responsible to anyone other than Marlowe for providing the protections afforded to clients of Cenkos nor for providing advice in relation to any matters referred to in this Announcement. Neither Cenkos nor any of its affiliates owes or accepts any duty, liability or responsibility to any person who is not a client of Cenkos in connection with this Announcement, any statement contained herein or otherwise.

 

Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), which is authorised by the German Federal Financial Supervisory Authority and subject to limited regulation by the FCA in the United Kingdom, is acting exclusively for Marlowe and no one else and will not be responsible to anyone other than Marlowe for providing the protections afforded to clients of Berenberg nor for providing advice in relation to any matters referred to in this Announcement. Neither Berenberg nor any of its affiliates owes or accepts any duty, liability or responsibility to any person who is not a client of Berenberg in connection with this Announcement, any statement contained herein or otherwise.

 

Publication on a website

 

In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available on the Company's website (https://www.marloweplc.com/investors/offer-for-restore-plc/) no later than 12 noon (London time) on the business day immediately following the date of this announcement. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

The person responsible for arranging the release of this announcement on behalf of Marlowe is Alex Dacre, Chief Executive Officer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRSFLSISEFSESA
Date   Source Headline
8th Apr 20242:54 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20244:45 pmRNSBlock listing Interim Review
18th Mar 20247:00 amRNSBoard Changes; Update re: Returns of Capital
26th Feb 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
22nd Feb 20247:00 amRNSDisposal and Directorate Change
15th Jan 202410:23 amRNSChange of Nominated Adviser and Joint Broker
30th Nov 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSInterim results for the six months to 30 Sept 2023
23rd Nov 20237:00 amRNSNotice of Interim Results
31st Oct 20234:30 pmRNSTotal Voting Rights
27th Sep 20235:18 pmRNSHolding(s) in Company
26th Sep 20233:23 pmRNSBlock Admission
13th Sep 20236:15 pmRNSResult of AGM
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 20221:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.